Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Advances in Therapy|April 20, 2024
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A PodcastLuciano J Costa, Paula Rodriguez-Otero
Hematology. American Society of Hematology. Education Program|December 9, 2022
Cellular therapy for multiple myeloma: what's now and what's nextPaula Rodriguez-Otero, Jesús F San-Miguel
Cancer Treatment Reviews|October 1, 2021
Roadmap to cure multiple myelomaPaula Rodriguez-Otero, Bruno Paiva, Jesús F San-Miguel
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 8, 2023
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical ImpactHitomi Hosoya, Paula Rodriguez-Otero, Surbhi Sidana, et al.
Ejhaem|November 29, 2023
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial resultsMarc S Raab, Elena Zamagni, Salomon Manier, et al.
Clinical Therapeutics|November 5, 2021
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE StudySujith Dhanasiri, Georgia Hollier-Hann, Catherine Stothard, et al.
European Journal of Haematology|July 1, 2022
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and ItalyKatja Weisel, Astrid Ottosson Wadlund, Guntug Gungor, et al.
Hemasphere|July 2, 2026
Multiple myeloma: A tale of deregulated transcription factorsNahia Gómez-Echarte, Edurne San José-Enériz, Estíbaliz Urizar-Compains, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
High-Risk Multiple Myeloma: Redefining Risk and Rethinking TherapyGareth J Morgan, Dennis D Lee, Nisha S Joseph, et al.
Leukemia & Lymphoma|April 26, 2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myelomaPaula Rodriguez-Otero, Dieter Ayers, Shannon Cope, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Advances in Therapy|April 20, 2024
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A PodcastLuciano J Costa, Paula Rodriguez-Otero
Hematology. American Society of Hematology. Education Program|December 9, 2022
Cellular therapy for multiple myeloma: what's now and what's nextPaula Rodriguez-Otero, Jesús F San-Miguel
Cancer Treatment Reviews|October 1, 2021
Roadmap to cure multiple myelomaPaula Rodriguez-Otero, Bruno Paiva, Jesús F San-Miguel
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 8, 2023
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical ImpactHitomi Hosoya, Paula Rodriguez-Otero, Surbhi Sidana, et al.
Ejhaem|November 29, 2023
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial resultsMarc S Raab, Elena Zamagni, Salomon Manier, et al.
Clinical Therapeutics|November 5, 2021
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE StudySujith Dhanasiri, Georgia Hollier-Hann, Catherine Stothard, et al.
European Journal of Haematology|July 1, 2022
Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and ItalyKatja Weisel, Astrid Ottosson Wadlund, Guntug Gungor, et al.
Hemasphere|July 2, 2026
Multiple myeloma: A tale of deregulated transcription factorsNahia Gómez-Echarte, Edurne San José-Enériz, Estíbaliz Urizar-Compains, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 28, 2026
High-Risk Multiple Myeloma: Redefining Risk and Rethinking TherapyGareth J Morgan, Dennis D Lee, Nisha S Joseph, et al.
Leukemia & Lymphoma|April 26, 2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myelomaPaula Rodriguez-Otero, Dieter Ayers, Shannon Cope, et al.
Pageof 8